Ivonescimab plus chemotherapy failed a cost-effectiveness assessment in China at current pricing, according to an economic evaluation published in BMC Health Services Research. The analysis concluded the regimen was not cost-effective from the perspective modeled, even as the therapy is being positioned as an emerging first-line option for advanced squamous non-small cell lung cancer. The report highlights how payer math can determine real-world adoption even when clinical programs show promise, especially for expensive antibody-drug or immune-based regimens. For developers, the evaluation underscores the growing importance of pricing, reimbursement thresholds, and evidence planning that supports both clinical value and health-economic value. Net effect: economic hurdles could slow uptake unless pricing adjusts or stronger comparative effectiveness data emerge.